BlackRock Fund Advisors’s Zevra Therapeutics ZVRA Stock Holding History

BlackRock Fund Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$117K	Sell	2,472 -12,050	-83%	-$740K	﹤0.01%	3566
2016 Q3	$1.04M	Buy	14,522 +824	+6%	+$58.6K	﹤0.01%	3227
2016 Q2	$872K	Buy	13,698 +1,087	+9%	+$179K	﹤0.01%	3271
2016 Q1	$2.93M	Buy	12,611 +1,078	+9%	+$261K	﹤0.01%	2966
2015 Q4	$3.67M	Buy	11,533 +10,591	+1,124%	+$2.88M	﹤0.01%	2985
2015 Q3	$292K	Sell	942 -25	-3%	-$7.66K	﹤0.01%	3349
2015 Q2	$284K	Buy	+967	New	+$211K	﹤0.01%	3390

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.4B AUM 33.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock Fund Advisors's ZVRA Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Zevra Therapeutics (ZVRA) stake by 83% in Q4 2016, selling an estimated $740K and leaving 2,472 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

BlackRock Fund Advisors first reported a position in ZVRA in Q2 2015 and has held it in 7 quarters since. The position peaked at $3.67M in Q4 2015. 36 funds tracked by Wall St. Rank hold ZVRA as of Q4 2016.

BlackRock Fund Advisors held 2,472 shares of Zevra Therapeutics worth $117K as of Q4 2016.
BlackRock Fund Advisors sold 12,050 Zevra Therapeutics shares in Q4 2016, an estimated $740K.
Zevra Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3566 holding.
BlackRock Fund Advisors first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's Zevra Therapeutics position peaked at $3.67M in Q4 2015.
36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.